TCS Targets Net Zero Emissions by 2030
3.6.2021 12:28:00 EEST | Business Wire | Press release
Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has announced its plans to reduce its absolute greenhouse gas emissions across Scope 1 and Scope 2 by 70% by 2025 (over 2016 base year), and to achieve net zero emissions by 2030.
In its recently published Integrated Annual Report 2020-21, the company has set forth this new carbon reduction goal after having achieved the previous target of reducing its specific carbon footprint by half by 2020 (versus baseline year FY 2008), ahead of schedule. In FY 2021, TCS’ specific carbon footprint across Scope 1 and Scope 2 was lower by 61.6% compared to baseline year FY 2008.
At the core of TCS’ strategy to reduce its carbon footprint is improved energy efficiency through the addition of more green buildings to the company’s real estate portfolio, reduction of IT system power usage, and the use of TCS Clever Energy™, which leverages IoT, machine learning and AI to optimize energy consumption across campuses. TCS’ Vision 25x25 is a strategic lever that delinks TCS’ business growth from campus expansion, and brings down emissions related to employee commutes and business travel. Other elements of its net zero aspiration include greater use of renewable sources of energy and carbon removal offsets.
“Our net zero goal underlines our renewed commitment to environmental stewardship. To curb emissions and limit global warming to well below 2, preferably to 1.5 degrees Celsius, compared to pre-industrial levels, all organizations will have to reimagine existing business models and aim for sustainable growth. We are in a unique position to combine our purpose-driven world view with digital innovation to not only drive our own sustainability, but also partner with customers, civil society and governments to lead and shape solutions for a sustainable future,” said N G Subramaniam, COO & Executive Director, TCS.
TCS’ environmental footprint was significantly reduced in FY 2021 due to the large-scale switch to remote working, enabled by its Secure Borderless Workspaces™ operating model. With over 97% of employees working from home throughout the year, resource consumption, emissions and wastes were significantly lower. During the year, the company’s absolute energy consumption came down by 46.6% over the prior year, and absolute carbon footprint (Scope 1 + Scope 2) by 48.8%.
TCS will also continue its efforts in water conservation and waste management through reduction and recycling initiatives. All its campuses ensure zero biodegradable waste to landfill and zero water discharge. TCS has also eliminated the use of single-use plastics across campuses and ensured the recycling of all recyclable plastic waste.
TCS is certified under the ISO 14001:2015 Environmental Management System standard, across 120 locations globally. The company was recently awarded a Gold rating in the EcoVadis 2021 Sustainability Assessment, for the eighth consecutive year. TCS outperformed its peers in all four key areas of measurement: Environment, Labor and Human Rights, Ethics, and Sustainable Procurement.
About Tata Consultancy Services (TCS)
Tata Consultancy Services is an IT services, consulting and business solutions organization that has been partnering with many of the world’s largest businesses in their transformation journeys for over 50 years. TCS offers a consulting-led, cognitive powered, integrated portfolio of business, technology and engineering services and solutions. This is delivered through its unique Location Independent Agile™ delivery model, recognized as a benchmark of excellence in software development.
A part of the Tata group, India's largest multinational business group, TCS has over 488,000 of the world’s best-trained consultants in 46 countries. The company generated consolidated revenues of US $22.2 billion in the fiscal year ended March 31, 2021, and is listed on the BSE (formerly Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. TCS' proactive stance on climate change and award-winning work with communities across the world have earned it a place in leading sustainability indices such as the MSCI Global Sustainability Index and the FTSE4Good Emerging Index. For more information, visit www.tcs.com and follow TCS news at @TCS_News .
To stay up-to-date on TCS global news, follow @TCS_News.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005462/en/
Contact information
TCS media contacts:
Asia Pacific
Email: charlene.lee@tcs.com | Phone: +65 9138 4370
Australia and New Zealand
Email: kelly.ryan@tcs.com | Phone: +61 422 989 682
Benelux
Email: joost.galema@tcs.com | Phone: +31 615 903387
Canada
Email: tia.thomas@tcs.com | Phone: +1 647 790 7602
Europe
Email: mattias.afgeijerstam@tcs.com | Phone: +46 723 989 188
India
Email: saxena.kritika@tcs.com | Phone: +91 22 6778 9999
Email: vanshika.sood@tcs.com | Phone: +91 22 67789098
Japan
Email: douglas.foote@tcs.com | Phone: +81 80-2115-0989
Latin America
Email: martin.karich@tcs.com | Phone: +569 6170 9013
Middle East & Africa
Email: s.hasneen@tcs.com | Phone: +971567471988
Nordics
Email: roland.bagen@tcs.com | Phone: +46 70 317 80 24
UK
Email: peter.devery@tcs.com | Phone: +44 20 3155 2421
USA / Canada
Email: william.thomas@tcs.com | Phone: +1 203-984-3978
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 202620.10.2026 16:02:00 EEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators, academic institutions, and Guardant’s public-private partners using the company’s technologies and/or real-world data, underscoring the wide adoption of its platform across the research community. “At ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinic
First Cessna Citation CJ4 Gen3 Advances Toward Entry Into Service as First Production Unit Rolls out of the Factory20.10.2026 16:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, recently celebrated the rollout of the first production unit of the Cessna Citation CJ4 Gen3, an important milestone as the aircraft advances toward entry into service. The rollout represents Textron Aviation's continued investment in the light jet lineup, bringing Garmin G3000 PRIME avionics, Garmin Emergency Autoland and other customer-driven enhancements to the proven Citation CJ4 platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020982419/en/ First Cessna Citation CJ4 Gen3 advances toward entry into service as first production unit rolls out of the factory. (Photo credit: Textron Aviation) “This rollout is a visible result of the care, precision and teamwork that move an aircraft from design intent to a production-ready airplane,” said Eric Cardinali, senior vice president, Manufacturing Operations. “For our manufacturing teams, it represents the discipl
ARIS Launches Process Context for Enterprise AI, Reinforcing Position as the Essential Platform for AI Ecosystem20.10.2026 15:00:00 EEST | Press release
ARIS, the pioneer in business process management whose powerful Enterprise Model has been the foundation for enterprise operations for more than three decades, today launched Process Context for Enterprise AI – to become the critical base layer for the agentic ecosystem, giving agents and applications the business understanding they need to deliver measurable new value. While Process Context is becoming critical for successfully deploying and scaling enterprise AI, it demands far more than simply connecting AI agents to business data. It requires a comprehensive foundation that captures the relationships between processes, people, systems, risks and controls. Built on a comprehensive Digital Twin of the Organization that connects how work is designed with the execution data that sits around it, ARIS provides this critical layer of Process Context from more than 30 years of enterprise knowledge and experience, something new entrants to the space are struggling to replicate. The importan
Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation20.10.2026 15:00:00 EEST | Press release
Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020837126/en/ Hologic and Inpeco S.A. announce a co-marketing partnership for Inpeco's automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab X‘s open automation capabilities, laboratories can achieve high-throughput workflows with the potential to increase sample volumes1 and enhance end-to-end sample traceability2, supporting reliable test results for optimal patient outcomes.3 The Panther System will i
Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma20.10.2026 15:00:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase 1/Phase 2 clinical updates at the European Society for Medical Oncology (ESMO) Congress (Madrid, Spain, 23-27 October). During the event, Debiopharm will highlight clinical updates on its pipeline targeting the DNA Damage Response (DDR), featuring single-agent data on zedoresertib (Debio 0123) as well as rational combination strategies, with both temozolomide in glioblastoma and with lunresertib (Debio2513) in solid tumors. Debiopharm’s planned activities at ESMO 2026 include: Rapid Oral Presentation (Debio 0123-GBM-105 / NCT05765812): Presenting dose escalation data evaluating zedoresertib in combination with temozolomide in patients with recurrent or progressive glioblastoma. Poster Presentation (Debio 0123-102 / NCT05109975): Presenting Phase 1 expansion data evaluating s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
